384 related articles for article (PubMed ID: 18181176)
1. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays.
Håkansson P; Segal D; Lassen C; Gullberg U; Morse HC; Fioretos T; Meltzer PS
Exp Hematol; 2004 May; 32(5):476-82. PubMed ID: 15145216
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
[TBL] [Abstract][Full Text] [Related]
4. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
5. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
6. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.
Merkerova M; Bruchova H; Brdicka R
Leuk Res; 2007 May; 31(5):661-72. PubMed ID: 17070905
[TBL] [Abstract][Full Text] [Related]
9. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
Zámecníkova A; Al Bahar S; Ramesh P
Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
13. [Molecular pathogenesis of chronic myeloid leukemia].
Sasaki K; Mitani K
Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
[TBL] [Abstract][Full Text] [Related]
14. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
15. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
16. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
Bruennert D; Czibere A; Bruns I; Kronenwett R; Gattermann N; Haas R; Neumann F
Leukemia; 2009 May; 23(5):983-5. PubMed ID: 19052557
[No Abstract] [Full Text] [Related]
17. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
19. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
20. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]